Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.33 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.33 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.33 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.33 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.33 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.33 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.33 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.33 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.33 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.33 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14725788 | 0.84 | CA1 (0.38) | MEN1KMT2AMAPTUSP2ALOX15 | |
| SCHEMBL1648543 | 0.83 | CA12 (0.37) | MEN1KMT2AMAPTUSP2ALOX15 | |
| SCHEMBL1648538 | 0.83 | CA1 (0.37) | MEN1KMT2AMAPTUSP2ALOX15 | |
| SCHEMBL1648540 | 0.83 | MEN1 (0.36) | MEN1KMT2AMAPTUSP2ALOX15 | |
| SCHEMBL1648693 | 0.80 | CA2 (0.36) | MEN1KMT2AMAPTUSP2ALOX15 | |
| SCHEMBL1650155 | 0.79 | MEN1 (0.36) | MEN1KMT2AMAPTUSP2ALOX15 | |
| SCHEMBL435766 | 0.79 | ALDH1A1 (0.44) | MEN1KMT2AMAPTHPGDLMNA | |
| SCHEMBL18801112 | 0.78 | MEN1 (0.35) | MEN1KMT2AMAPTUSP2ALOX15 | |
| SCHEMBL436677 | 0.78 | MEN1 (0.40) | MEN1KMT2AMAPTUSP2ALOX15 | |
| SCHEMBL30004264 | 0.78 | MEN1 (0.40) | MEN1KMT2AMAPTUSP2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486004-B1 | SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | ZAFGEN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2486004-B1 | SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | ZAFGEN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-02-25 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067905-B2 | Sulphone compounds and methods of making and using same | ZAFGEN, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | ZAFGEN, INC. | 2013-02-28 | — | — | US | disclosed |
| EP-2486004-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen Corporation (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044506-A2 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051531-A1 | SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, STS | MEN1 1603/4885KMT2A 666/4885MAPT 3145/4885 |
| US-20130053364-A1 | Sulphone Compounds and Methods of Making and Using Same | METAP2, DNPEP, STS | MEN1 1603/4885KMT2A 666/4885MAPT 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.